Company: Eli Lilly & Co.
Job title: Associate Vice President, Medical Diabetes & Incretin Early Clinical Research
Illuminating Small Molecule Oral Agonists in the Clinic to Redefine a New Paradigm in Obesity 8:30 am
Weight loss, diabetes remission and cardiovascular improvements in a pill: reformulating a potent small molecule GLP-1 RA in the clinic Investigating the current state of play in developing oral incretins Delineating clinical breakthroughs in obesity and T2D drug development to define the unmet medical need and inform the next steps in drug developmentRead more
day: Day One